维得利珠单抗与抗TNF药物在IBD患者中的严重感染风险比较
基于美国两个全国性商业保险数据库和法国全国性健康保险数据库,纳入2010年后启动维得利珠单抗或抗TNF药物的成人IBD患者,经倾向评分匹配后比较严重感染风险。整体IBD队列中两组风险无差异(HR 0.95),但UC患者使用维得利珠单抗风险降低(HR 0.68),CD患者未见降低(HR 1.10)。
要点
- 整体IBD队列中维得利珠单抗与抗TNF的严重感染风险无显著差异。
- UC患者使用维得利珠单抗严重感染风险低于抗TNF(HR 0.68)。
- CD患者使用维得利珠单抗与抗TNF的严重感染风险无显著差异。
核心结论
- 维得利珠单抗在整体IBD患者中严重感染风险与抗TNF无差异,但UC患者风险降低而CD患者未降低。
研究设计与样本
- 基于美国两个全国性商业保险数据库和法国全国性健康保险数据库的队列研究。
- 纳入2010年后启动维得利珠单抗或抗TNF的18岁及以上CD和UC患者,按既往抗TNF暴露分层。
- 经1:4可变比例倾向评分匹配后,纳入8768例维得利珠单抗启动者和26656例抗TNF启动者。
主要发现
- 随访37725人年期间共发生893例严重感染。
- UC患者中维得利珠单抗严重感染风险降低(HR 0.68;95%CI 0.50-0.93)。
- CD患者中维得利珠单抗与抗TNF风险无差异(HR 1.10;95%CI 0.87-1.38)。
- UC患者排除胃肠道感染后,维得利珠单抗仍与较低严重感染风险相关(HR 0.59;95%CI 0.39-0.90)。
临床怎么用
- 在UC患者中选择维得利珠单抗时,可考虑其相对抗TNF较低的严重感染风险。
- 在CD患者中,维得利珠单抗与抗TNF的严重感染风险未见差异,决策需综合其他因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The risk of serious infections associated with vedolizumab in patients with inflammatory bowel disease (IBD) is uncertain. We assessed the risk of serious infections associated with use of vedolizumab versus anti-TNF in patients with IBD, according to IBD subtype and previous exposure to anti-TNF. METHODS: Based on two U.S. nationwide commercial insurance databases and the French nationwide health insurance database, anti-TNF naïve and experienced patients diagnosed with Crohn's disease (CD) and ulcerative colitis (UC) aged 18 years or older who initiated vedolizumab or an anti-TNF agent after 2010 were identified. Hazard ratios for serious infections comparing vedolizumab and anti-TNF were estimated in propensity score matched cohorts. RESULTS: Among 8768 vedolizumab and 26,656 anti-TNF initiators included after 1:4 variable ratio propensity score matching, 893 serious infections occurred during 37,725 person-years of follow-up. The risk of serious infections was not different between vedolizumab and anti-TNF in the overall IBD cohort (HR, 0.95; 95% CI, 0·79-1.13), while the risk was decreased for vedolizumab users in patients with UC (HR, 0.68; 95% CI, 0.50-0.93), but not CD (HR, 1.10; 95% CI, 0.87-1.38). In patients with UC, vedolizumab was consistently associated with lower risk of serious infections after exclusion of gastrointestinal infections (HR, 0.59; 95% CI, 0.39-0.90). CONCLUSIONS: While the risk of serious infections associated with vedolizumab was not different compared to anti-TNF in the overall group of patients with IBD, the risk varied according to IBD subtype, by decreasing in patients with UC, but not CD. These findings may help to clarify the optimal position of vedolizumab in the therapeutic management of IBD.
引用
- Kirchgesner J, Desai RJ, Beaugerie L, et al. Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2020. PMID: 33387667. doi:10.1016/j.cgh.2020.12.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。